Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Multiple sclerosis

Oligoclonal bands still yield clues about multiple sclerosis

Oligoclonal bands are present in the cerebrospinal fluid of most patients with multiple sclerosis (MS) and represent a useful diagnostic measure. Two recent studies indicate that the identification of such bands might provide insight into the underlying mechanism of disease in MS and guide the treatment of individuals with this disorder.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lundkvist, M., Greiner, E., Hillert, J. & Fogdell-Hahn, A. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta. Mult. Scler. 16, 796–800 (2010).

    Article  CAS  Google Scholar 

  2. Bosca, I. et al. Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands. Mult. Scler. 16, 810–815 (2010).

    Article  CAS  Google Scholar 

  3. Garcia-Barragan, N. et al. Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment. Eur. J. Neurol. 16, 380–385 (2009).

    Article  CAS  Google Scholar 

  4. Owens, G. P. et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann. Neurol. 65, 639–649 (2009).

    Article  CAS  Google Scholar 

  5. Avasarala, J. R., Cross, A. H. & Trotter, J. L. Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch. Neurol. 58, 2044–2045 (2001).

    Article  CAS  Google Scholar 

  6. Joseph, F. G. et al. CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J. Neurol. Neurosurg. Psychiatry 80, 292–296 (2009).

    Article  CAS  Google Scholar 

  7. Hauser, S. L. et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N. Engl. J. Med. 358, 676–688 (2008).

    Article  CAS  Google Scholar 

  8. Piccio, L. et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch. Neurol. 67, 707–714 (2010).

    Article  Google Scholar 

  9. Bar-Or, A. et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann. Neurol. 67, 452–461 (2010).

    Article  CAS  Google Scholar 

  10. Paz Soldan, M. M. et al. Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Mol. Cell. Neurosci. 22, 14–24 (2003).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anne H. Cross.

Ethics declarations

Competing interests

A. H. Cross has acted as a consultant for and on the speakers' bureau of Bayer Healthcare, Pfizer and Biogen Idec. She has also acted as a consultant for Hoffman-La Roche. G. F. Wu declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cross, A., Wu, G. Oligoclonal bands still yield clues about multiple sclerosis. Nat Rev Neurol 6, 588–589 (2010). https://doi.org/10.1038/nrneurol.2010.142

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2010.142

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research